RB1 and neoplasm: Effectively, OTX2 knockdown (KD) by siRNA or downregulation through treatment with ATRA resulted in less proliferation and increased cell death in cell lines and tumor growth reduction in vivo, suggesting that OTX2 could indeed link multiple tumor-driving pathways involving CRX, C-MYC and RB phosphorylation [123].